Genentech brings ops savvy, pipeline to Roche

Despite its pipeline-enhancing objective, the acquisition of Genentech by Roche is showing a nod by the centenarian drugmaker to the upstart's operations talents. Genentech scientists are stepping into key manufacturing jobs for Roche--global manufacturing chief Pat Yang and North American commercial ops chief Ian Clark are two examples.

Similarly, Genentech operations have fared well in a post-merger manufacturing shake-up.  The Swiss drug giant closed its Palo Alto, CA, facility and cut hundreds of jobs in New Jersey.

By a more common metric, Genentech's generated revenue per employee of $1.2 million in 2008 bests Roche's $528,000, according to Bloomberg.

- here's the article

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.